TB Bioscience is a biotechnology company developing a novel point-of-care diagnostic test for tuberculosis to replace the 125 year old sputum smear test. TB Biosciences is working with a diverse group of small proteins that are present in humans who have active Tuberculosis. These proteins were discovered by examining the genome of the Tuberculosis bacteria. The proteins and the antibodies they detect in blood are not present in the latent or patients negative for Tuberculosis. Instead, the markers are present when Tuberculosis is active and a danger to the patient and those nearby. Using TB Biosciences unique approach, the company is continuing to develop and test its protein library with Tuberculosis positive patients as well as those with HIV and other respiratory diseases. Using combinations of peptides, the Company has achieved sensitivity/specificity higher than 90%.
